Equillium presents positive interim clinical data of itolizumab in first-line treatment of acute graft-versus-host disease at the 2021 transplantation and cellular therapy meetings digital experience

Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use

EQ Ratings Summary

EQ Quant Ranking